Checks out so far.

“In the NHS-Galleri trial's evaluable intervention participants across three annual rounds, the multi-cancer early-detection test had 99.50–99.60% specificity and 26.7–37.2% episode sensitivity for all cancers; these performance analyses were descriptive and the trial's primary late-stage-cancer endpoint was not met.”

3 of 4 review checks done · 1 counted · 2 by the author only

Supported · 0.9925 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited. The number is model-conditional, not a share of truth.